

A randomised double-blind study to compare two regimens of Levonorgestrel in emergency contraception in Nigeria

Submission date 19/03/2004	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered
Registration date 01/04/2004	Overall study status Completed	<input type="checkbox"/> Protocol
Last Edited 09/02/2011	Condition category Pregnancy and Childbirth	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr D Chikamata

Contact details

World Health Organization
20 Avenue Appia
Geneva
Switzerland
CH-1211
chikamatad@who.int

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

WHO/HRP ID: A15062

Study information

Scientific Title

Study objectives

Compare two regimens of levonorgestrel for emergency contraception in seven centres in Nigeria.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration.

Study design

Multicentre controlled randomised double-blind two-arm clinical trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Other

Study type(s)

Prevention

Participant information sheet

Health condition(s) or problem(s) studied

Contraception

Interventions

1. Levonorgestrel two doses of 0.75 mg 12 hours apart
2. Levonorgestrel one dose of 1.5 mg

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Levonorgestrel

Primary outcome measure

Efficacy, side-effects and timing of next menstrual period at six weeks.

Secondary outcome measures

No secondary outcome measures

Overall study start date

01/08/2002

Completion date

01/08/2004

Eligibility**Key inclusion criteria**

1. Requesting emergency contraception within 120 hours of unprotected intercourse
2. Only one act of unprotected intercourse during current cycle
3. Willing to abstain from further acts during current cycle
4. Regular menstrual cycles (24 to 42 days)
5. Having at least one spontaneous cycle before current cycle
6. Available for follow-up in the next six weeks
7. Negative pregnancy test
8. Willing to participate
9. Not breastfeeding
10. No use of hormonal contraceptives or of rhythm or natural family planning method of contraception during current cycle
11. Not unsure about the date of last menstrual period

Participant type(s)

Patient

Age group

Adult

Sex

Female

Target number of participants

3150 total, 450 per centre, 1575 per group

Key exclusion criteria

Does not comply with the above inclusion criteria.

Date of first enrolment

01/08/2002

Date of final enrolment

01/08/2004

Locations**Countries of recruitment**

Nigeria

Switzerland

Study participating centre
World Health Organization
Geneva
Switzerland
CH-1211

Sponsor information

Organisation
World Health Organization (WHO) (Switzerland)

Sponsor details
20 Avenue Appia
Geneva
Switzerland
CH-1211

Sponsor type
Research organisation

Website
<http://www.who.int/en/>

ROR
<https://ror.org/01f80g185>

Funder(s)

Funder type
Research organisation

Funder Name
World Health Organization (WHO) (Switzerland)

Alternative Name(s)
, , Всемирная организация здравоохранения, Organisation mondiale de la Santé,
Organización Mundial de la Salud, WHO, , ВОЗ, OMS

Funding Body Type

Private sector organisation

Funding Body Subtype

International organizations

Location

Switzerland

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/10/2002		Yes	No
Results article	results	01/10/2010		Yes	No